Strategic TPS collaboration Stablix is actively forming high-profile partnerships, notably with Vertex Pharmaceuticals, to advance targeted protein stabilization therapeutics. This signals openness to co-development and licensing deals that can expand reach and de-risked programs for potential partners.

Biotech scale fit With 11-50 employees and a multi-city presence (New York City and Boston), Stablix appears to be in a growth phase suitable for mid- to late-stage partnering, licensing discussions, and potential equity investments as they scale their TPS/TDT platform.

Innovative modality The focus on targeted deubiquitination therapeutics and targeted protein stabilization positions Stablix in a novel modality space. This creates cross-sell opportunities with investors and pharma companies seeking differentiated, first- or best-in-class technologies.

Validated interest Public recognition as a Fierce 15 company and participation in industry summits (TPD) indicate credibility and ongoing visibility in the biotech ecosystem, making outreach more credible to potential collaborators and funders.

Funding signals Current funding of $63M and reported revenue in the mid-range suggest the company has financial runway for partnering discussions, pilot programs, or stage-gated collaborations that can be aligned with potential customers’ development timelines.